Ectin Research AB (XSAT:ECTIN B) Total Liabilities : kr2.52 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB Total Liabilities?

Ectin Research AB's Total Liabilities for the quarter that ended in Mar. 2024 was kr2.52 Mil.

Ectin Research AB's quarterly Total Liabilities increased from Sep. 2023 (kr2.04 Mil) to Dec. 2023 (kr2.23 Mil) and increased from Dec. 2023 (kr2.23 Mil) to Mar. 2024 (kr2.52 Mil).

Ectin Research AB's annual Total Liabilities increased from Aug. 2020 (kr1.12 Mil) to Dec. 2022 (kr2.33 Mil) but then declined from Dec. 2022 (kr2.33 Mil) to Dec. 2023 (kr2.23 Mil).

Ectin Research AB Total Liabilities Historical Data

The historical data trend for Ectin Research AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB Total Liabilities Chart

Ectin Research AB Annual Data

Trend

Aug19

Aug20

Dec22

Dec23

Total Liabilities

0.88

1.12

2.33

2.23

Ectin Research AB Quarterly Data
	Aug19	Aug20	Mar21	Sep21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial								2.35	1.76	2.04	2.23	2.52

Ectin Research AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ectin Research AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.499	+	(0.73	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2.23

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	6.428	-	4.199
	=	2.23

Ectin Research AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.788	+	(0.76	+	-0.03
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2.52

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	4.418	-	1.9
	=	2.52

Ectin Research AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ectin Research AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.ectinresearch.com

Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB Headlines

No Headlines